In AF with recent ACS or PCI, apixaban improved 30-day outcomes vs. VKAs; aspirin effects varied vs. placebo.

In AF with recent ACS or PCI, apixaban improved 30-day outcomes vs. VKAs; aspirin effects varied vs. placebo. Ann Intern Med. 2020 Sep 15;173(6):JC29 Authors: Hoffer EP Abstract SOURCE CITATION: Alexander JH, Wojdyla D, Vora AN, et al. Risk/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS. Circulation. 2020;141:1618-27. 32223444. PMID: 32926823 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32926823?dopt=Abstract

Source: Annals of Internal Medicine - September 14, 2020 Category: Internal Medicine Authors: Hoffer EP Tags: Ann Intern Med Source Type: research